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Silent myocardiai ischemia own far more frequently than 
do anginai symptoms in patients with known coronary artery 
disease (l-3). In patients with stable exertional antiina. silent 
ischemic events occur despite control of symptoms with 
conventional antianginal drugs (4). Because silent myocar- 
dial ischemia is not associated with any patient discomfort. 
treatment is generally not considered necessary. However. 
silent ischemia during daily life is associated wth an in- 
creased risk of coronary events and cardiac death tS_7). 
Antianginal therapy should possibly be directed toward 
control of lotal ischemic burden. i.e.. symptomatic and silent 
ischemia (8). 
Several studies (9-D) tzave evaluated the effects of 
various drugs on the number. magnitude and duration of 
episodes of-ST segment depress&in patients with angina 
pectoris. However, most of these studies provide only 
indirect evaluation of therapy for silent &hernia since they 
were primarily conducted for testing .he efficacy of antiangi- 
nal drugs on angina frequency and ischemic threshold during 
exercise testing. Although some recent studies have specif- 
ically evaluated the role of beta-adrcncrgr blockers (13). 
fJ Am cdl CardioI 1991;17.963-9) 
mtrates 1141 and calcium channel antagonists (ISI in patients 
with sdent myocardial &hernia. direct comparison among 
the various clauses of anti-ischemic drugs is lacking. This 
study was designed to assess and compare the anti-ischemic 
effects of titra:ed doses of atenolol and nifedipine on tran- 
Gent trchemlc events detected during ambulat&y electrocar- 
diographic ECGl monitoring in patients with stable angina. 
Pat% sekcticm. Men with chronic exertional angina (26 
months’ duration) and documented coronary anery d&ax 
were enrolled from the cardiolqy clinks of the Fresw Veter- 
an:, Alfan Medial Center between February I. 1988 and 
December 31.1988. The protocol and informed consent were 
approved by the centUs human study and research commit- 
tee5 m November 1987. AU patients gave written informed 
consent for participation before enrollment in the study. 
Comnar? wren’ disense was docummrcd by one or more 
of the pllwinp: coronary anery stenosis defined as a7lW 
luminal diameter narrowing of one or more major coronary 
arterie,: reversible perfusion defects on exercise thallium- 
ZOt rcintigraphy; or presewe of Q waves diagnostic of 
myocardml mfarction on the 12 lead ECG. All patients had 
evidence of exercise-indilced ischemia before entry into the 
study. Pauents were excluded if they had conditions that 
precluded the use cf a beta-blocker or a calcium channel 
blocker. These included significant bronchospasm or emphy- 
sema. grea,er than first degree atrioventricular (AV) blwk 
conge*dve heart failure or sinus bradycardia 150 beatslmin 
Iwithwt medication). and those with past hypersensitivity to 
After the first active treatment phase all patients entered 
a second I week placebo period followed by crossnver 10 the 
alternate treatment for 3 mnre weeks. The dorcs of study 
medications were titrated in similar fashion as described 
earlier. Ambulatorv ECG monitor& was rwformed et I 
week and at the enh of this phase. - 
Ambdatary ECC mmdtinr. Continuous 48 h two chan- 
I IT 7 
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Figure 1. Study pri~tocol. The duration of the study was 8 to 9 
weeks. Palients took sublingual nitmglycerin as needed fnr angina. 
Afrer the initial placebo permd patients received in a randomized 
double blind manner ~te”cdoI or nifedipine for I week fallowed by 2 
more weeks of active treatment. This was followed by a second 
placebo p&ad and crus~uver tothe alternate trcatmax. At the end 
of each placebo and active lrealmem priadr 48 h ambulatory 
eleuroeardiogaphie monimring (AEM) was performed. 
bewblockers or calcium channel antagonists. Also excluded 
were patients with conditions (left bundle branch block. 
severe left ventricular hypertrophy. Wolff-Parkinson-White 
syndrome. pacemaker rhythms. uncorrected hypokalemia) 
or drugs (digitalis. tricyclic antidepressants) a&cling the ST 
segment. 
Sludy design (Fig. I). Therapy with nitrates, calcium 
channel blockers and beta-adrenergic blockers was stopped 
for a minimum of 48 h or 5 half-lives of the prescribed drugs 
before enrollment in the study. but sublingual nitroglycerin 
was provided for relief of angina1 symptoms. T+ study 
protocol (Fig. I) consisted of a placebo run-in single blind 
study qualificatian phase lasting 7 to IO days, during which 
time matching placebo drugs were administered and patients 
were asked to keep angina diaries. Patients underwent 
ambulatory ECG monitoring for 48 h at the end of the 
placebo phase. Far study qualification all patients were 
required to have evidence of ambulatory ischemia during 
daily life with a minimum offive ischemic episodes or a total 
duration of ischemia a5 min/48 h. Patients who fulfilled 
these criteria were randomly assigned in a double blind 
manner tn receive atenolol. 50 mg once daily (9~03 AM). nr 
nifedipine. 20 mg three times daily (9:OO AM. 4:tHl PM and 
I I :W PML for I week, when 48 h ambulatory ECG monitar- 
ing was repealed. If ischemia during ambulatory KG mon- 
itoring was abolished. the treatment was continued at the 
same dosage for 2 mure weeks. However, if ambulatory 
ECG monitoring at the end of I week revealed the presence 
of transient ix-hernia, the doses of study medications were 
increased: alenolol to I00 mg once daily or nifedipine to 
30’mg three times daily and continued for 2 mure weeks. 
Ambulatory ECG monitoring was rcpcatcd at the end of the 
3 week treatment period (Fig. I). 
nel ambulator ECG recordings were obtained at the end of 
placebo, withdrawal and active treatment phases with vali. 
dated and calibrated amplitude modulated (AM) rape- 
recorders (series SSGQ Holler recorder, Marquette Electron- 
ics) with a frequency-response between 0.05 and IO0 Hr. 
which meets Ihe American Heart Association standards for 
evaluation of rhr ST segment (16). A left precordial and an 
inferior or anterior ECC lead were selected and are- 
sponded to the location of maximal ST segment depression 
during the erercise treadmill test. The KG leads with Q 
waves or baseline ST segment depression were avoided. 
Baseline ECG recordings were made on each patient before 
and after hyperventilation. and in the supine. prone. sitting 
and standing positions toensure that the ST szgrnent was not 
affected by these changes in position. Patients were in- 
strutted to press an event button on the recorder if they 
experienced an episode of angbm and to ward the number 
and duration of episodes in a diary. The ambulatory KG 
monitoring tapes were scanned at M) to 120 times real time 
on a playback analyzer unil (8oM) Holler analysis system, 
Marquette electrunics) by an experienced technician for the 
presewx. frequency and duratiin of ischemic episodes. 
An ischemic episode ~(1s defined as 21 nun horizontal or 
downsloping ST depression measured SO as from the 1 point 
and lasting rl min. The onset of the ixhemic episode was 
defined as the time when the ST segment became depressed 
E I mm and the offset time was defined after ST depression 
became 41 mm. An interval of at least 2 min during which 
the ST segment returned to the baseline was required before 
another episode was counted. The technician scanning the 
Holler tapes identified all potential ischemic episodes meet- 
ing these criteria and recorded the time of onset. peak ST 
depression and tertnination of ischemic events. Ekctrocar- 
diographic tracings of these episodes were obtained at 
25 mm/s speed for review. In addition, hourly examples of 
baseline ST segment without changes were recorded on 
paper. For each patient, the total number and duration of 
episodes were determined every 24 h. All episodes of ST 
segment depression were identified as symptomatic or silent 
on the basis of details obtained from the patient’s diary. 
Real-time printouts showing ST segment abnornmlities 
were blindly and independently reviewed by at least two 
experienced investigators. In case of a discrepancy between 
the two observers, the tapes were reanalyzed. Only those 
recordings with interpretable signals for 840 h during the 
48 h monitoring period were included in the analysis. 
Stalistkal anrdysis. Continuous measures were assessed 
using two-sample I test: analyses of categorical variables 
were conducted using Fisher’s exact test. In the double- 
blind phase. analysis al the patients on each trealmen~ 
kilenolol or nifedipine) who had abolition of irchemic events 
by the end of the respective active treatment period was 
accerplishcd using Fisher’s exact test. The irchemic event- 
derived variables were evaluated using a repeated-measures 
crossover analysis of covariance. wi!h the baseline measure 
of interest serving as the covariate. after preli,.dnary test\ 
showed no evidence of stalislically sign/licant car&w 
etTecls from baseline to the end of the intervenina placebo 
washout period. Mean changes t=SEl within c& active 
treatment irom baseline to the end of the respective active 
treatment period were assessed using paired I tests. All 
statistical testing was performed at a two-sided signiiicana 
level of ao.05. 
Study palienfs (Table I). Of the 24 men enrolled. 5 acre 
excluded during the placebo run-in period because they did 
not meet the qualification criteria for randomiza!ion. Three 
additional patients were excluded from the efficacy analysis 
because there were no ambulatory ECG monitonng data 
during one of the active treatment phases. ihe anti-isciwk 
efficacy of atenolol and nifedipine war compared in the 
remaining 16 patients with analyzable data during bath 
active treatment periods. The baseline clinical chardcterw 
tics of there patients are shown in Table I. The mean age oi 
the group was 63 f g years. and the majority (9%) were 
Caucasian. All patients had an established history (average 
duration 7.4 + 5.4 years) of coronary artery disease with 
chronic exertional angina and eight patients had a history of 
previous (>6months) myocardial infarction. All patients had 
T&e 1. Baretine Ctinxat Chamcterirticr of 16 Patient\ 
Figm 1. Comptiwn of ad-irckmic effects on the frequency 
lupper) and dxation tbwwl of ischemic cpiscdes between the 
trcatmrn, grour~. Compared with placebo. both atenold ,- 
bar) and nifedxpine that&d bul rigniikantly tp <O.W decreased 
the number of ixhemic events during the monitoring period. How- 
ever. atenolol war sipnifantly better than nifedipim in reducing the 
frequency tp < O.OSI and duration tp c 0.01) dixkmic episodes. 
exercise-induced ixhemia as well as evidence of transient 
myocardial isckmia (five or more episodes or 25 min 
duratmnl48 hl duriw ambulatoN ECG monitorin& 
Hemodynmic &cts of study m+dicakas. Tlie-hearI rate 
response and blood pressure were evaluated with the patient 
seated. The heart rate during the placebo phase v/as 80 f 
2 beatrimin and was reduced significantly to 67 * 2 be& 
min during therapy with atenolol. In contrast. treatment with 
Fllre 3. Compariron of atenolol and niledipine in totally rupprerr 
ing ischemic setiviry. Treatment with atenolot abolished irchemic 
activity in nwre patrents. particularly duke the morning haun 
between 63” AM and t2:M) noan. 
nifedipine prcduced a slight increase in heart rate to 82 + 
I beats/min. The systolic blwd pressure was 145 + 4 min Hg 
during placebo and was reduced to 139 * 3 and 138 = 2 
during therapy with atenolol and nifedipine. respectively. 
During placebo. the diastolic blood pressure was 86 + 2 min 
Hg and WBE reduced to 78 + I and 79 + 2 mm Hg. 
respectively. during therapy. 
Ambulatwy ek&meardingmphk monitoring results. (Fig. 
2 and 3). During the placebo phase there was an average of 
16.4 2 3.7 episodes al transient myncardial ischemia. of 
which 97% were asymptomatic. The average duration of 
transient myocardial ischemia per patient WE 4.103 + 
I.071 s during the 48 h ambelatory ECG monitoring periud. 
Double blind therapy with atenulol or nifedipine produced a 
significant reduction in the number(p < 0.035 for both drugs) 
and duration (p ‘: 0.005 for bath drugs) of episodes com- 
pared with placebo IFig. 2). Comparison between the anti- 
iachemic elieels of the two drugs revealed that atenotal 
produced a significantly lp < 0.051 greater reduction in the 
average numberofsilent ischemic episodes (3.2 ? 0.7 vs. 6.2 
+ 1.3) as well as in the total duration of silent ischemia (634 
+ I55 vs. 1.2% + 276 s, p < 0.01) (Fig. 2). 
The evaluation of study medications in abolishing Iran. 
sient ischemia during the monitoring period revealed 
atenolol to bc mnre effective than nifedipine. Treatment with 
atenolol was associated with a total suppression of ischemic 
activity in SW% of patients compared with only a 25% 
suppression rate with nifedipine (Fig. 3). 
EUeeLs of therapy on the manittg surge d ambulatory 
&ehemk activity (Fig. 4 to 6). Because it is known that there 
is a surge in silent isehemic events between 6:tM AM and 
n~m. we evaluated the effects of study medications during 
this time period. During the placebo phase the hourly total 
number (Fig. 41 and duration (Fig. 5) of ischemic episodes 
showed a marked increase between 7~00 AM and I I:W AM. 
Fifty percent of the irchemic episodes occurred between 
6103 AM and noon. and accounted for 39% (I.609 + 468 11 of 
the total ischemic time per patient. Although both atenolol 
and nifedipine produced significant reductions in the number 
of ischemic episodes during these hours. treatment with 
atetwlol was significantly (p < 0.05) tnnre effective than 
treatment with nifedipine (Fig. 61. Only atenolol produced a 
significant reduction (p < 0.01) in the average duration uf 
silent ischemia per patient (I39 f 54 vs. I.@39 ? 468 s. p < 
0.011 during this period. The average duration per silent 
ischemic episode was also significantly (p < 0.005) reduced 
only with atenulul (62 f 21 vs. 208 * 24 s). Although the 
difference was not statistically significant. atenolnl abnlished 
the morning surge of ischemic activity in 64% of the patients 
compared with the suppression rate of 27% during therapy 
with nifedipine (Fig. 3). 
Advetw e&k.. Fewer adverse experiences were re- 
ported during atenolol therapy than were reported during 
treatment with nifedipine. During treatment with nifedipine 
dizziness was noted in five patients. peripheral edema in 
four. asthenia in four and paresthesia in two. In contrast. 
only twn patients rqwrted asthrraia during therapy with 
atenolol 
Figure 5. Hourly distribution of the total duration :- 
laecondrl af irchemic episcdcr between B:W A\( and 
a ‘IxI- 
- xc+- 
Discussion 
hllwgcncsis of slknt iscbcmii in palknts with angina. 
Appropriate selection of a therapeutic regimen should be 
based on the underlying pathophysiologic process. Although 
the precise mechanism of silent myoeardial ischemia has not 
been established, on the basis of data showing minimal or no 
increase in heart rate during the 5 to I5 min preceding silent 
isehemic events. it has be& postulated that-silent i$ihemla 
during daily life occurs predominantly as a result of decrease 
in cwwwy blood supply ll7.18). This concept has been 
further supparted by findings that show that heart rate fis 
significantly lower at the onset of silent irchemic cvcntr 
during daily lie than during exercise testing in the same 
patients (Ii). However. findings from rcc&t studies in 
palierds with chronic exertional angina demonstrate that 
most episodes ofambulatory silent ischemia arc preceded by 
a sipiftcant increase in hean rate and blood pressure 
119.20). Furthermore. silent ischemic events have been 
shown to increasc in frequency as well as duration during the 
morning hours when both heart rate and blood pressure have 
the greatest increases during the 24 h period (21). 
There data, along with the results of recent reports 
(10-13) showing beneficial effects of beta-blocking agents in 
the trcantcnt of silent ischemic episodes. have clearly 
established a role of increased myocardial oxygen demand in 
the pathogenesis of ambulato~~rilent iaeh&ia. Neienhc- 
less, some episodes of silent &hernia occur without any 
evidence for increased myoexdial oxygen demand and 
clearly must occur secondary to alterations it) coronary 
blocd supply 120). 
Prcvtcms tudits in therapy of silent isrhrmia. The anti- 
ischemic therapy for control of silent ixhemic events will 
vary depending on the clinical wbsets of patients being 
treated and the predominant mechanism rcspon$ihk for the 
ischemic episodes. All antianginal agents. includmg ottiates. 
adrenergic blockers (both alpha- and beta-blocking drugs1 
and calcium channel blockers. arc eiTcctive in the manage- 
ment of patients with angina pectoris and have been shown 
to reduce the number and duration of ST segment deprcssien 
during ambulatory ECG monitoring 19-12). However. most 
of these studier were primarily dcstgncd to demonstrate the 
antianginal efficacy of these drugs and did not specifically 
evaluate the effects on ambulatory siknt ixhemia. 
Several studies 113-U) have specifically evaluated the 
anti-ischemic effects of nitrates. beta-blockers and calcium 
channel blockers in patients with demonstrable silent myc- 
cardial Ischemin. Although the results of these studies show 
that all antianginal drugs arc effective in reducing the frc- 
quency and duration of silent ischemie evcntr. carcfttl eval- 
uation reveals considerable wiatian in their etXcaey. II has 
been suggested (13,15) that drugs that lower heart rate are 
more effective in controlling siknl iscbcmic cvcnt~ during 
dailv life. However. little information is available regarding 
direct comparison of anti-ischemic agents with different 
hemodynamic ifcets m the treatment of patients with am- 
Gent myocardial &hernia during routine daily activities. 
Anti-kcbemk c6wcy of ate&d amd nifcdpinc dwizg 
ambulatory ECG monitoring. This study shows that both 
atenolol and nifcdipine arc elTcctive m reducing the fw 
quency and duration of silent ischemic events during daily 
life. Alenolol was signilicantlv lo < 0.051 more effective than 
mfedipine in red&g the &age &nbcr and average 
duration of silent ischemic events during the monitoring 
period. Alca more patients 00% vs. 25%) were free ai silent 
ixhcmia during therapy with atcnolol. 
Although we cannot provide a specific reason for the 
difference in the anti-isehemic effieaey of alcnolol and nifed- 
ipine in this study. there arc several possible xplanations. 
Beta-blockers exert their beneficial effects in patients with 
angma pecloris primarily by reducing the heat? rate, systolic 
blood prcrrw and cardiac contractility (22.23). Because all 
of our patients had evidence oiexertional myoeardial ische- 
mia. it is likely that an increase in myoeardial oxygen 
demand played a significant role in the genesis ofambitlalory 
silent ischemia in these patients. Beeawe atctwlol produced 
a significant reduction in the heat rate response it is likely 
that this effect is partielly responsible for its greater anti- 
ischemic efficacy. Our results arc similar to those reported 
Flgwe 6. Ccmparison 0; e%ers of alenolol and nfcdipine an Ihe 
frequency rupprl and duration ttmrer~ of silent irchemic ep~&-s 
during the morning hours a16:W r\~ 10 t?:W nwnr Buih trca,men,s 
produced a significant reduction in the frequency of ircbemic 
episodes. but the t~rnment with atenolol produced a grearer tp c 
0.W reduction in the number of whemic episodes. Dunng the 
morning hours. only atenalol produced a sipnificam rp < 0.01) 
reduction in the averapc duration of ambulatory silent irchemia. 
prwiously with meroprolol in a smaller group of patients 
with silent myocardial ischemia (13). 
Treatment with nikdipine also produced a significant 
reduction in the number and duration of silent ischemic 
events: bowever. its anti-ischemic effects were less rcmark- 
able than :hose of atenolol. Although nifedipine was associ- 
ated with 8 smaller degree of reduction in blood presrure. it 
failed to lower the heart rate response, which may panly 
account for its lesser anti-ischemic efficacy in our patients. 
Role d stmald In reducing dknt Bohemia during Ihr early 
maning hours. The a~cnolol was rigniticanlly more effec- 
tive tp < 0.05) thw nifedipine in suppressing the ischemic 
activity during the morning hours hetwvwn 6~00 aa and noon 
IFig. 61. This bugge\ts significant residual anti-ixhemic 
et&cl of atenolol 24 h after dosing and is consistent with 
previous data 04) showing sustained heta.blocking efficacy 
of atcnolol during a Gmilar dosing schedule. Because nifcd- 
ipine has a relatively shorter halfWe I6 lo tl h) and was given 
nt I I:00 PM and 993 AM. it is possible that a therapeutic gap 
existed between 6~00 AM and lO:OO AM (Fig. 4 and 5). 
Although this hypothesis is not established. the morning 
surge in transient ischemic events may act as a trigger for 
acute myocardial infarction and sudden cardiac death, which 
occur with increased frequency during this time period. The 
anti-ischemic effects of atenolol in suppressing the morning 
surge of ischemic activity may prove beneficial in reducing 
the risk of myocardial infarction and sudden cardiac death 
(251. 
Conelusions. Atenolol and nifedipine are e&ctive anti- 
ischemic drugs in the treatment of ambulatory silent isch 
emia. In most patients. atenolol effectively reduced the 
morning surge of irchcmic activity and abolished silent 
ischemia between 6:OO AM and nwn. Treatment with 
atenolol may reduce the risk of acute myocardial infarction 
and sudden cardiac death by suppressing silent ischemic 
events. particularly during the morning hours when the risk 
of these events is significantly increased. Large controlled 
studier are needed. however. to document the knelicial 
efkcts of anti-ischemic therapy in patients with ambulatory 
silent ischemia. 

